Which treatment sequence best reflects the speaker's approach to anemia in lower-risk MDS?
ESAs for symptomatic anemic patients who are not yet transfusion-dependent; luspatercept when ESA response is lost, or upfront in patients who are transfusion-dependent but not heavily so; imetelstat for heavily transfusion-dependent patients or those who lose response to luspatercept
Imetelstat first-line for all transfusion-dependent patients, with luspatercept reserved for patients who fail imetelstat
Luspatercept first-line for all anemic patients, including those not transfusion-dependent, with ESAs reserved for heavily transfusion-dependent patients